Skip to content
Stocks News
Enter Ticker Symbol
  • Home
  • FEATURED COMPANY
  • ANALYST COVERAGE
  • NEWS
  • SUBSCRIBE
  • CONTACT

ANALYST COVERAGE

axos-financial-‘ahead-of-its-time,’-analyst-applauds-digital-first-strategy

Axos Financial ‘Ahead of Its Time,’ Analyst Applauds Digital-First Strategy

Oct 12, 2024

Needham analyst Kyle Peterson initiated coverage on Axos Financial, Inc. AX with a Buy rating and a price…

Read more
this-amazon-analyst-begins-coverage-on-a-bullish-note;-here-are-top-5-initiations-for-friday

This Amazon Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Oct 11, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…

Read more
what-to-expect-when-johnson-&-johnson-reports-q3-earnings-next-week?

What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week?

Oct 11, 2024

What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week? Monday, Johnson & Johnson (NYSE:JNJ) said…

Read more
this-amazon-analyst-begins-coverage-on-a-bullish-note;-here-are-top-5-initiations-for-friday

This Amazon Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Oct 11, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…

Read more
conocophillips-preps-for-offense-with-$9b-cash-return:-analyst-–-conocophillips-(nyse:cop),-marathon-oil-(nyse:mro)

ConocoPhillips Preps For Offense With $9B Cash Return: Analyst – ConocoPhillips (NYSE:COP), Marathon Oil (NYSE:MRO)

Oct 11, 2024

JPMorgan’s Arun Jayaram just initiated coverage of ConocoPhillips COP with a Neutral rating and a price target of…

Read more
recently-listed-cancer-firm-onkure’s-innovative-approach-to-breast-cancer-treatment-sparks-analyst-enthusiasm

Recently Listed Cancer Firm OnKure’s Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm

Oct 11, 2024

Oppenheimer initiated coverage on OnKure Therapeutics Inc OKUR. Last week, OnKure Therapeutics completed its merger with Reneo Pharmaceuticals Inc.…

Read more
servicenow-(now)-stock-forecast-and-price-target-2024-$now

ServiceNow (NOW) Stock Forecast and Price Target 2024 $NOW

Oct 11, 2024

ServiceNow – Analysts’ Recommendations and Stock Price Forecast (2024) MarketBeat calculates consensus analyst ratings for stocks using the…

Read more
pdd-(pdd)-stock-forecast-and-price-target-2024-$pdd

PDD (PDD) Stock Forecast and Price Target 2024 $PDD

Oct 11, 2024

PDD – Analysts’ Recommendations and Stock Price Forecast (2024) MarketBeat calculates consensus analyst ratings for stocks using the…

Read more
this-fastenal-analyst-begins-coverage-on-a-bullish-note;-here-are-top-5-initiations-for-monday

This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Oct 10, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…

Read more
southstate-(nasdaq:ssb)-research-coverage-started-at-citigroup

SouthState (NASDAQ:SSB) Research Coverage Started at Citigroup

Oct 10, 2024

Citigroup started coverage on shares of SouthState (NASDAQ:SSB – Free Report) in a research note released on Thursday…

Read more
2-analyst-calls-to-pay-attention-to:-stocks-to-rise-double-digits

2 Analyst Calls to Pay Attention To: Stocks to Rise Double-Digits

Oct 10, 2024

Analysts’ sentiment is important in determining the right time to buy stock. However, the trend in sentiment and…

Read more
joby-aviation-(joby)-stock-forecast-and-price-target-2024-$joby

Joby Aviation (JOBY) Stock Forecast and Price Target 2024 $JOBY

Oct 10, 2024

Joby Aviation – Analysts’ Recommendations and Stock Price Forecast (2024) MarketBeat calculates consensus analyst ratings for stocks using…

Read more
  1. Pages:
  2. «
  3. 1
  4. ...
  5. 274
  6. 275
  7. 276
  8. 277
  9. 278
  10. 279
  11. 280
  12. ...
  13. 381
  14. »

Posts pagination

Newer posts Page 1 … Page 277 … Page 381 Older posts

The content presented on this site is intended solely for entertainment purposes and should not be construed as an invitation to engage in the purchase or sale of securities. Each content provider featured on 10x Wealth Report brings a unique perspective and predisposition, which may not necessarily align with that of 10x Wealth Report. It is crucial to recognize that 10x Wealth Report is not a registered financial advisor or firm. Read More full disclaimer

CATEGORIES

  • FEATURED COMPANY
  • NEWS
  • ANALYST COVERAGE
  • Special Post
  • CONTACT
  • SUBSCRIBE
  • Privacy Policy
  • Terms or Service
  • Disclaimer

CONNECT & FOLLOW

© 10x Wealth Report Copyright 2024.